Hera BioLabs is a contract research organization (CRO) utilizing gene editing technologies to create enabling preclinical research models for oncology & immuno-oncology. Hera’s platform model, the OncoRat SRG, is a SCID rat on the Sprague-Dawley background harboring a double knockout for the Rag2 and Il2rgamma genes. This enhanced immunodeficient rat model has a severely impaired immune system lacking B-cells, T-cells, and NK-cells. The OncoRat overcomes limitations of mouse models for xenograft efficacy studies. For example, the OncoRat enables tumor cell line xenograft models that were previously inefficient or not feasible in mouse models. While the long timeline required for the establishment of patient derived xenografts or PDX models in mice is often impractical; the OncoRat grows ~10x larger tumors enabling PDX establishment and efficacy studies in fewer passages and a shorter amount of time.

Latest Hera News

Preclinical Oncology Insights

Check out the latest updates from our quarterly newsletter which provides information on new R&D, publications, model development & industry trends in the three categories below.